MaltSci 麦伴科研

Appearance

Popular Reports / microbiology

This report is written by MaltSci based on the latest literature and research findings

How does microbiome dysbiosis contribute to disease? ​

Abstract ​

The human microbiome is a complex ecosystem that plays a crucial role in maintaining health and homeostasis. Dysbiosis, characterized by an imbalance in microbial communities, has emerged as a significant contributor to the pathogenesis of various diseases, including metabolic disorders, autoimmune diseases, and mental health conditions. This review synthesizes current research on the mechanisms through which microbiome dysbiosis contributes to disease, focusing on immune dysregulation, increased inflammation, and altered metabolic processes. Key factors leading to dysbiosis include antibiotic use, dietary changes, and environmental influences, which collectively disrupt microbial diversity and function. The consequences of dysbiosis extend beyond the gut, affecting systemic health and the gut-brain axis, thereby linking gut health to mental well-being. Therapeutic implications such as probiotics, prebiotics, and fecal microbiota transplantation offer promising strategies to restore microbial balance. However, challenges remain in understanding the complex interactions between dysbiosis and health. This review aims to provide a comprehensive overview of how microbiome dysbiosis contributes to disease, highlighting the urgent need for further research to explore innovative therapeutic strategies that leverage the microbiome for improved health outcomes.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Understanding the Microbiome
    • 2.1 Composition and Diversity of the Human Microbiome
    • 2.2 Role of the Microbiome in Health
  • 3 Mechanisms of Dysbiosis
    • 3.1 Factors Contributing to Dysbiosis
    • 3.2 Biological Mechanisms Linking Dysbiosis to Disease
  • 4 Dysbiosis and Specific Diseases
    • 4.1 Dysbiosis in Metabolic Disorders
    • 4.2 Dysbiosis and Autoimmune Diseases
    • 4.3 The Gut-Brain Axis: Dysbiosis and Mental Health
  • 5 Therapeutic Implications
    • 5.1 Probiotics and Prebiotics
    • 5.2 Fecal Microbiota Transplantation
    • 5.3 Dietary Interventions
  • 6 Future Directions and Research Gaps
    • 6.1 Emerging Technologies in Microbiome Research
    • 6.2 Need for Longitudinal Studies
  • 7 Conclusion

1 Introduction ​

The human microbiome, a complex ecosystem of trillions of microorganisms residing in and on our bodies, plays a critical role in maintaining health and homeostasis. Recent advancements in microbiome research have highlighted its profound influence on various physiological processes, including metabolism, immune function, and even mental health. Dysbiosis, defined as an imbalance in microbial communities, has emerged as a significant factor in the pathogenesis of numerous diseases, including metabolic disorders, autoimmune diseases, and mental health conditions [1][2][3]. Understanding the mechanisms through which microbiome dysbiosis contributes to disease is essential for developing novel therapeutic strategies aimed at restoring microbial balance and improving health outcomes.

The significance of the microbiome in health cannot be overstated. Microbial communities vary across different body sites, such as the gut, oral cavity, skin, and respiratory tract, each playing unique roles in maintaining local and systemic health [1]. For instance, the gut microbiome is crucial for digestion, nutrient synthesis, and the development of the immune system [4]. However, dysbiosis can disrupt these functions, leading to chronic inflammation and disease [5]. As the prevalence of chronic diseases continues to rise globally, understanding the link between dysbiosis and disease pathogenesis has become increasingly urgent [6].

Research has identified various factors contributing to dysbiosis, including antibiotic use, dietary changes, and environmental influences [7][8]. Antibiotics, for example, can drastically alter the composition of the gut microbiome, reducing microbial diversity and promoting the overgrowth of pathogenic species [9]. Dietary patterns, too, play a significant role in shaping the microbiome, with high-fat and low-fiber diets being associated with adverse microbial shifts [10]. Furthermore, environmental factors, such as exposure to pollutants and changes in lifestyle, can further exacerbate dysbiosis [11].

The consequences of dysbiosis are far-reaching, impacting host immune responses, metabolic processes, and even the gut-brain axis. Dysbiosis has been linked to the development of autoimmune diseases, with altered microbial composition triggering inflammatory responses that contribute to disease progression [2][12]. Similarly, dysbiosis has been implicated in mental health disorders, where the gut microbiome influences neuroinflammation and neurotransmitter production [8]. This complex interplay between the microbiome and host health underscores the need for a comprehensive understanding of the biological mechanisms linking dysbiosis to disease.

This review is organized into several key sections. First, we will explore the composition and diversity of the human microbiome, emphasizing its roles in health. Next, we will discuss the mechanisms of dysbiosis, detailing the factors that contribute to microbial imbalance and the biological pathways linking dysbiosis to disease. Following this, we will examine specific diseases associated with dysbiosis, including metabolic disorders, autoimmune diseases, and mental health conditions, with a focus on the gut-brain axis. We will also discuss therapeutic implications, including the use of probiotics, prebiotics, and fecal microbiota transplantation as potential interventions to restore microbial balance. Finally, we will highlight future research directions and existing gaps in knowledge that need to be addressed to fully understand the implications of microbiome dysbiosis in health and disease.

By synthesizing current research findings and identifying critical areas for further investigation, this review aims to provide a comprehensive overview of how microbiome dysbiosis contributes to disease, ultimately paving the way for innovative therapeutic strategies that leverage the microbiome to enhance health outcomes.

2 Understanding the Microbiome ​

2.1 Composition and Diversity of the Human Microbiome ​

Microbiome dysbiosis, defined as an imbalance in the structural and functional properties of the microbiome, has been implicated in the pathogenesis of a variety of diseases. This condition arises when the normal microbial community composition is altered, leading to a reduction in microbial diversity and the proliferation of pathobionts, which can exacerbate inflammation and contribute to disease development.

One of the primary mechanisms by which dysbiosis contributes to disease is through the disruption of immune homeostasis. Dysbiosis can trigger a pro-inflammatory response by modulating the host immune system. For instance, alterations in the gut microbiome can lead to "leaky gut syndrome," characterized by increased intestinal permeability. This condition allows the translocation of bacteria and other endotoxins into systemic circulation, eliciting an inflammatory response that can affect various organs and systems, thereby contributing to diseases such as diabetes and cardiovascular diseases (CVDs) [1].

In the context of specific diseases, dysbiosis has been associated with inflammatory bowel disease (IBD) and periodontitis. In IBD, dysbiosis results in a decrease in microbial diversity, which is crucial for maintaining gut health. The imbalance can lead to a predominance of pathogenic bacteria that exacerbate inflammation [13]. Similarly, in periodontitis, the dysbiotic oral microbiome disrupts homeostasis, leading to increased virulence of microbial communities and enhanced immune responses that promote tissue destruction [13].

Furthermore, dysbiosis has been linked to metabolic disorders, including diabetes mellitus. Research indicates that changes in the gastrointestinal tract microbiome can alter gut fermentation profiles and intestinal wall integrity, resulting in metabolic endotoxemia and low-grade inflammation, which are critical in the pathogenesis of diabetes [14]. The alterations in microbial composition can also influence the host's metabolic pathways, further exacerbating the disease [15].

In addition to inflammatory and metabolic diseases, dysbiosis is implicated in autoimmune conditions. The immune system's response to dysbiotic microbiota can lead to the activation of autoreactive T cells, contributing to the development of autoimmune diseases [16]. Dysbiosis can also promote chronic inflammation, which is a common feature in many autoimmune diseases [5].

The interplay between dysbiosis and disease is complex and multifactorial. Factors such as diet, antibiotic use, and environmental changes can influence the composition of the microbiome, leading to dysbiosis. The keystone-pathogen hypothesis suggests that certain low-abundance pathogens can disrupt a healthy microbiota, transforming it into a dysbiotic state that favors disease [17]. Understanding these mechanisms is crucial for developing microbiome-targeted therapies that could potentially restore balance and improve health outcomes in affected individuals.

In summary, microbiome dysbiosis contributes to disease through mechanisms that involve immune dysregulation, increased inflammation, and altered metabolic functions. The complexity of these interactions highlights the need for continued research to elucidate the precise pathways through which dysbiosis impacts health and to explore therapeutic interventions that can restore microbial balance.

2.2 Role of the Microbiome in Health ​

Microbiome dysbiosis, characterized by an imbalance in the microbial communities within the host, plays a significant role in the development and progression of various diseases. Dysbiosis can be defined as a reduction in microbial diversity, a loss of beneficial taxa, and an increase in pathogenic microorganisms. This imbalance has been linked to numerous health issues, including inflammatory diseases, autoimmune disorders, metabolic diseases, and even certain cancers.

One critical aspect of dysbiosis is its impact on the immune system. The gut microbiota interacts with the immune system to maintain homeostasis; however, when dysbiosis occurs, it can lead to a pro-inflammatory state. This dysregulated immune response is associated with conditions such as inflammatory bowel disease (IBD), autoimmune diseases, and metabolic syndromes [2][5]. For instance, dysbiosis has been implicated in the exacerbation of autoimmune diseases by triggering inflammatory pathways that can disrupt normal immune function [2].

In addition to its immune-modulating effects, dysbiosis can influence the nervous system through the gut-brain axis. Changes in the gut microbiome have been associated with neurological conditions such as autism and attention deficit hyperactivity disorder (ADHD), highlighting the interconnectedness of gut health and mental health [18]. The gut microbiota's ability to produce neurotransmitters and other signaling molecules further emphasizes its role in regulating brain function and behavior [18].

Dysbiosis is also closely linked to metabolic diseases. For example, alterations in gut microbiota composition can affect energy metabolism and fat storage, contributing to obesity and insulin resistance [19]. Studies have shown that specific microbial taxa are enriched or depleted in individuals with metabolic disorders, suggesting that the microbiome's composition can directly influence metabolic health [6].

Furthermore, dysbiosis has been associated with the progression of liver diseases. The gut microbiome plays a crucial role in maintaining intestinal permeability and regulating liver function. Dysbiosis can lead to increased intestinal permeability, allowing translocation of microbial products into the bloodstream, which can trigger inflammatory responses in the liver and contribute to conditions such as non-alcoholic fatty liver disease and cirrhosis [20][21].

In summary, microbiome dysbiosis contributes to disease through several mechanisms, including immune dysregulation, alterations in metabolic processes, and interactions with the central nervous system. The loss of microbial diversity and the imbalance of beneficial and pathogenic microorganisms can disrupt homeostasis and promote inflammatory pathways, ultimately leading to various health complications. Understanding these connections is crucial for developing targeted therapeutic strategies aimed at restoring a healthy microbiome and mitigating the effects of dysbiosis on health.

3 Mechanisms of Dysbiosis ​

3.1 Factors Contributing to Dysbiosis ​

Microbiome dysbiosis, characterized by an imbalance in microbial communities, has been implicated in the pathogenesis of various diseases through several mechanisms. Dysbiosis often leads to a reduction in microbial diversity and the loss of beneficial taxa, alongside an increase in pathogenic microorganisms. This imbalance can disrupt essential microbiota functions necessary for maintaining health, thereby promoting disease states.

One of the primary mechanisms through which dysbiosis contributes to disease is through its impact on the immune system. Dysbiosis is associated with a pro-inflammatory state, which can exacerbate metabolic diseases, autoimmune conditions, and infectious diseases. For instance, studies have shown that dysbiosis can trigger chronic inflammation by modulating host immune responses and altering the production of immune mediators. This dysregulation is evident in conditions such as inflammatory bowel disease (IBD), where changes in microbiota composition can lead to heightened inflammation and disease progression [22].

Environmental factors play a significant role in the development of dysbiosis. Key contributors include dietary changes, antibiotic use, and alterations in living conditions. For example, early life exposure to antibiotics has been linked to a loss of microbial diversity in the gut, which correlates with an increased risk of allergic diseases and atopy [23]. Furthermore, dietary habits can influence microbiome composition, with diets high in processed foods being associated with lower microbial diversity [6].

The gut microbiome begins its development at birth, with significant transitions occurring during breastfeeding and the introduction of solid foods. This developmental phase is critical, as a diverse and rich gut microbiome during early life is essential for establishing a stable microbiota into adulthood and preventing dysbiosis [23]. Disruptions during this sensitive period can have long-lasting effects on health.

Dysbiosis has also been linked to specific diseases beyond gastrointestinal disorders. For instance, alterations in the gut microbiota have been associated with neurodevelopmental disorders such as autism and attention deficit hyperactivity disorder (ADHD), highlighting the microbiome's influence on brain health [18]. Similarly, dysbiosis has been implicated in liver diseases, where an altered microbiome can contribute to the severity and progression of conditions like non-alcoholic fatty liver disease and cirrhosis [19].

Moreover, dysbiosis can lead to systemic effects by allowing the translocation of microbial products into the bloodstream, which can further influence inflammatory processes and contribute to multi-organ dysfunction, particularly in critically ill patients [24]. The leaky gut hypothesis suggests that increased intestinal permeability associated with dysbiosis allows harmful substances to enter the circulation, potentially exacerbating liver disease and other systemic conditions [21].

In summary, microbiome dysbiosis contributes to disease through mechanisms involving immune dysregulation, environmental factors, and developmental disruptions. The interplay between these elements underscores the complexity of microbiome-related health outcomes and the need for targeted therapeutic strategies to restore microbial balance and promote health.

3.2 Biological Mechanisms Linking Dysbiosis to Disease ​

Dysbiosis refers to the imbalance of microbial communities within the gut microbiome, which can significantly contribute to the pathogenesis of various diseases through several biological mechanisms. These mechanisms can be broadly categorized into four main areas: impaired intestinal mucosal barrier function, inflammation activation, immune dysregulation, and metabolic abnormalities.

Firstly, dysbiosis disrupts the intestinal mucosal barrier, leading to increased intestinal permeability often referred to as "leaky gut." This condition allows microbial products and toxins to translocate into the bloodstream, triggering systemic inflammation and contributing to the development of diseases such as inflammatory bowel disease (IBD) and liver diseases [21]. The leaky gut hypothesis posits that translocating microbial products can initiate and exacerbate liver disease, highlighting the importance of maintaining gut barrier integrity [21].

Secondly, dysbiosis is associated with the activation of inflammatory pathways. The alteration in the composition of the gut microbiota can lead to an overrepresentation of pro-inflammatory bacteria and a decrease in beneficial bacteria. This shift results in the production of inflammatory cytokines, such as TNF-α, which can further exacerbate chronic inflammatory conditions [13]. In the context of periodontitis, for example, dysbiosis has been shown to enhance the virulence of oral microbial communities, which can trigger inflammatory responses that are detrimental to oral and systemic health [13].

Immune dysregulation is another critical mechanism linking dysbiosis to disease. The gut microbiota plays a vital role in modulating immune responses. Dysbiosis can lead to an imbalance in the immune system, promoting a pro-inflammatory state while impairing regulatory mechanisms. This dysregulation has been implicated in various autoimmune diseases, where the immune system mistakenly targets the body’s own tissues [2]. Research indicates that the interaction between dysbiotic microbiota and the immune system can lead to increased susceptibility to autoimmune conditions [2].

Lastly, dysbiosis can cause metabolic abnormalities. Changes in the gut microbiome can affect the metabolism of nutrients and the production of metabolites that are crucial for host health. For instance, a reduction in microbial diversity is often observed in metabolic diseases such as obesity and type 2 diabetes, where the microbiome’s ability to ferment dietary fibers into short-chain fatty acids (SCFAs) is compromised [15]. SCFAs play a vital role in maintaining gut health and regulating metabolic processes, and their deficiency due to dysbiosis can contribute to metabolic disorders [15].

In summary, microbiome dysbiosis contributes to disease through mechanisms that include the disruption of the intestinal barrier, activation of inflammatory pathways, immune system dysregulation, and metabolic disturbances. Understanding these biological mechanisms is essential for developing targeted therapeutic strategies aimed at restoring microbial balance and preventing disease progression [25][26][27].

4 Dysbiosis and Specific Diseases ​

4.1 Dysbiosis in Metabolic Disorders ​

Microbiome dysbiosis, characterized by an imbalance in the composition and function of gut microbiota, plays a significant role in the development and progression of various metabolic disorders. The relationship between dysbiosis and metabolic diseases such as obesity, type 2 diabetes, and metabolic syndrome is multifaceted and involves several underlying mechanisms.

Firstly, dysbiosis is associated with alterations in the production of microbial metabolites, particularly short-chain fatty acids (SCFAs) like butyrate and propionate. These metabolites are crucial for maintaining gut health and metabolic homeostasis. For instance, butyrate has been shown to exert anti-inflammatory effects and may act as a tumor suppressor, while propionate can influence energy metabolism. Dysbiosis often leads to reduced production of these beneficial metabolites, which can contribute to the pathogenesis of metabolic disorders by promoting low-grade inflammation and insulin resistance [28].

Furthermore, dysbiosis can disrupt the integrity of the intestinal barrier, leading to increased intestinal permeability, often referred to as "leaky gut." This condition allows gut-derived products, including lipopolysaccharides (LPS), to enter the systemic circulation, triggering systemic inflammation and contributing to metabolic dysfunction [29]. The inflammatory response initiated by LPS and other pro-inflammatory factors can further exacerbate insulin resistance and metabolic syndrome [30].

Additionally, dysbiosis has been linked to the modulation of host immune responses. The gut microbiota plays a critical role in regulating immune function, and an imbalance can lead to chronic inflammation, which is a hallmark of metabolic disorders [31]. For example, changes in the gut microbiome can affect the secretion of gastrointestinal hormones that regulate appetite and metabolism, leading to increased food intake and weight gain [32].

The connection between dysbiosis and specific metabolic disorders is also supported by evidence indicating that alterations in gut microbiota composition can influence the development of conditions such as non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases [32][33]. In the case of NAFLD, dysbiosis may promote liver inflammation and fibrosis through mechanisms involving altered bile acid metabolism and increased oxidative stress [34].

In summary, microbiome dysbiosis contributes to metabolic disorders through mechanisms that include the production of beneficial metabolites, disruption of the intestinal barrier, modulation of immune responses, and alterations in appetite-regulating hormones. These pathways highlight the importance of maintaining a balanced gut microbiome for metabolic health and suggest that interventions aimed at restoring microbiota balance, such as the use of probiotics and prebiotics, may hold therapeutic potential in managing metabolic disorders [35][36].

4.2 Dysbiosis and Autoimmune Diseases ​

Microbiome dysbiosis plays a significant role in the pathogenesis of autoimmune diseases through various mechanisms that involve immune dysregulation, increased intestinal permeability, and aberrant metabolite signaling. Dysbiosis refers to an imbalance in the microbial communities within the gut, which can lead to inflammatory and autoimmune responses.

One of the central hypotheses regarding dysbiosis is that it contributes to autoimmune pathogenesis by disrupting the delicate balance of immune homeostasis. Specifically, dysbiosis can lead to a depletion of short-chain fatty acids (SCFAs), which are crucial for maintaining intestinal barrier integrity and modulating immune responses. The imbalance between T helper 17 (Th17) cells and regulatory T (Treg) cells, often exacerbated by dysbiosis, is another key factor in the development of autoimmune disorders such as rheumatoid arthritis (RA), type 1 diabetes (T1D), multiple sclerosis (MS), and inflammatory bowel disease (IBD) [37].

Furthermore, dysbiosis is associated with the production of inflammatory metabolites and altered signaling pathways, which can trigger autoimmune reactions. For instance, microbial metabolites can influence the activation of immune cells and the production of pro-inflammatory cytokines, leading to a systemic inflammatory state that promotes autoimmunity [38].

The interaction between the microbiome and the immune system is bidirectional; while dysbiosis can contribute to autoimmune diseases, the immune system also shapes the composition of the microbiota. An altered immune state can create an environment conducive to dysbiosis, which in turn amplifies autoimmunity [39]. This complex interplay highlights the importance of maintaining a balanced microbiome to prevent the onset of autoimmune conditions.

Clinical and preclinical data support the notion that restoring microbial balance through interventions such as probiotics, prebiotics, and fecal microbiota transplantation (FMT) can ameliorate autoimmune symptoms. These therapies have been shown to modulate cytokine profiles, enhance epithelial integrity, and promote Treg induction, suggesting that targeting gut-immune crosstalk could provide a mechanism-based approach for managing autoimmune diseases [37].

In summary, dysbiosis contributes to autoimmune diseases by disrupting immune homeostasis, increasing intestinal permeability, and producing inflammatory metabolites. Understanding these mechanisms is crucial for developing microbiome-targeted therapies that could provide new avenues for the treatment and management of autoimmune disorders.

4.3 The Gut-Brain Axis: Dysbiosis and Mental Health ​

Microbiome dysbiosis, characterized by an imbalance in microbial communities, has been increasingly recognized for its significant role in various diseases, including those affecting mental health through the gut-brain axis. The gut microbiota contributes to host health by modulating immune responses, producing metabolites, and influencing the central nervous system (CNS). Dysbiosis, which often manifests as a reduction in microbial diversity and an increase in pathogenic organisms, can disrupt these essential functions and lead to a range of health issues.

Research indicates that dysbiosis is linked to the development and progression of numerous inflammatory diseases, including neurological disorders. For instance, dysbiosis is observed in conditions such as anxiety, depression, and autism spectrum disorders. The mechanisms by which dysbiosis affects mental health may involve several pathways. One prominent hypothesis is that dysbiosis alters the production of gut-derived metabolites, such as short-chain fatty acids (SCFAs), which are crucial for maintaining gut integrity and influencing neuroinflammation. A reduction in beneficial metabolites can impair the gut-brain communication, exacerbating mental health issues.

Additionally, dysbiosis can lead to increased intestinal permeability, often referred to as "leaky gut." This condition allows for the translocation of microbial products and toxins into the bloodstream, which can trigger systemic inflammation and affect brain function. Elevated levels of inflammatory cytokines, resulting from dysbiosis, have been implicated in mood disorders and cognitive decline.

Furthermore, the gut-brain axis facilitates bidirectional communication between the gut microbiota and the CNS. Changes in the gut microbiome can influence the hypothalamic-pituitary-adrenal (HPA) axis, thereby affecting stress response and emotional regulation. For example, studies have shown that certain gut bacteria can produce neurotransmitters like serotonin and gamma-aminobutyric acid (GABA), which play critical roles in mood regulation. Dysbiosis may disrupt the synthesis and availability of these neurotransmitters, further contributing to mental health disorders.

Clinical approaches to address dysbiosis and its impact on mental health include microbiota modulation strategies, such as the use of probiotics, prebiotics, and dietary interventions aimed at restoring a healthy microbial balance. Fecal microbial transplantation has also emerged as a potential therapeutic option to restore microbiota diversity and function, although more research is needed to establish its efficacy in mental health contexts.

In summary, microbiome dysbiosis contributes to disease through multiple mechanisms, particularly by disrupting gut-brain communication, altering immune responses, and affecting the production of crucial metabolites. Understanding these connections is vital for developing targeted interventions aimed at mitigating the impact of dysbiosis on mental health and overall well-being [1][5][40].

5 Therapeutic Implications ​

5.1 Probiotics and Prebiotics ​

Microbiome dysbiosis refers to an imbalance in the microbial composition of the gut, which has been linked to a variety of diseases, including chronic inflammatory conditions, metabolic disorders, and gastrointestinal diseases. Dysbiosis can disrupt the homeostasis of the gut microbiota, leading to increased intestinal permeability, inflammation, and systemic effects that contribute to the pathogenesis of various diseases.

Dysbiosis is closely associated with several chronic diseases, such as obesity, type 2 diabetes mellitus, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and even colorectal cancer. The alteration in gut microbiota composition can trigger chronic inflammation, which may lead to conditions like metabolic syndrome and chronic kidney disease (CKD) due to increased production of pro-inflammatory factors and uremic toxins [31][41][42]. The loss of microbial diversity and stability can also result in heightened susceptibility to infections and impaired immune responses [5][42].

Therapeutically, probiotics and prebiotics have emerged as potential strategies to modulate dysbiosis and restore microbial balance. Probiotics are live microorganisms that confer health benefits when administered in adequate amounts. They can help in re-establishing a healthy gut microbiota by increasing the abundance of beneficial bacteria, such as Bifidobacteria and Lactobacilli, while reducing potentially harmful bacteria [43]. Prebiotics, on the other hand, are dietary fibers that serve as substrates for beneficial gut microbes, promoting their growth and activity [44].

The use of probiotics and prebiotics has shown promise in ameliorating symptoms associated with dysbiosis-related diseases. For instance, in the context of metabolic disorders, probiotics and prebiotics have been reported to improve specific symptoms and reduce inflammatory markers [31]. In gastrointestinal diseases, such as IBD and IBS, microbiome-targeted therapies, including probiotics and dietary modifications, have been highlighted as effective strategies to restore microbial balance and alleviate disease symptoms [42].

However, the effectiveness of probiotics and prebiotics can vary significantly based on the specific strains used, the dosage, and the duration of treatment. More research is needed to determine the optimal strains and formulations for specific conditions [31][42]. Furthermore, the therapeutic applications of probiotics and prebiotics are still being explored, and while evidence suggests their beneficial roles in managing dysbiosis, additional studies are necessary to establish comprehensive guidelines for clinical practice [41][42].

In summary, microbiome dysbiosis contributes to disease through mechanisms involving chronic inflammation, impaired immune function, and altered metabolic processes. Probiotics and prebiotics offer promising therapeutic avenues for restoring gut health and managing dysbiosis-related conditions, but further research is essential to optimize their use in clinical settings.

5.2 Fecal Microbiota Transplantation ​

Microbiome dysbiosis, defined as an imbalance in the microbial communities within the human body, has emerged as a significant factor contributing to a variety of diseases. This condition is characterized by a reduction in microbial diversity and an overrepresentation of pathogenic organisms, which can disrupt host homeostasis and lead to various health issues.

The role of dysbiosis in disease pathogenesis is multifaceted. It has been implicated in gastrointestinal disorders, autoimmune diseases, metabolic syndromes, and even neurological conditions. For instance, in the context of inflammatory bowel diseases (IBD), dysbiosis can exacerbate inflammation and compromise mucosal barrier integrity, leading to increased intestinal permeability and systemic inflammation [45]. Additionally, dysbiosis is associated with altered immune responses, which can contribute to conditions such as allergies and autoimmune disorders [46].

Fecal microbiota transplantation (FMT) has gained traction as a therapeutic strategy aimed at correcting dysbiosis. FMT involves transferring fecal material from a healthy donor to a recipient with dysbiosis, thereby restoring a balanced microbial community. This innovative approach has shown promise in treating recurrent Clostridium difficile infections, where traditional antibiotic therapies have failed [47]. The efficacy of FMT in this context is notable, with reported cure rates ranging from 80% to 90% [48].

Beyond gastrointestinal disorders, FMT is being explored for its potential benefits in a range of other conditions linked to dysbiosis. Research has indicated that FMT may improve metabolic outcomes in conditions like obesity and diabetes, with studies showing enhanced insulin sensitivity following transplantation of microbiota from lean donors [49]. Furthermore, FMT has been investigated for its effects on neurological disorders, such as Parkinson's disease and multiple sclerosis, suggesting that microbiota composition may influence neuroinflammatory processes [49].

Despite the encouraging findings, the application of FMT is not without challenges. Variability in donor selection criteria, standardization of transplant protocols, and long-term safety data remain critical issues that need to be addressed [45]. Moreover, while FMT has generally mild to moderate transient adverse effects, rare severe complications underscore the necessity for rigorous donor screening and administration protocols [48].

In summary, microbiome dysbiosis is a critical factor in the development of various diseases, and FMT represents a promising therapeutic intervention aimed at restoring microbial balance. Ongoing research is essential to fully understand the implications of FMT and to refine its application across a broader spectrum of dysbiosis-related conditions.

5.3 Dietary Interventions ​

Microbiome dysbiosis refers to an imbalance in the composition and functionality of the gut microbiota, which has been linked to various diseases. This dysbiosis can result from multiple factors, including dietary habits, stress, antibiotic use, and lifestyle choices, ultimately leading to a range of health issues, particularly gastrointestinal disorders.

Dysbiosis is associated with several gastrointestinal diseases, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and colorectal cancer. The human gut microbiota plays a crucial role in maintaining gastrointestinal health, and its disruption can lead to increased intestinal permeability, often referred to as "leaky gut syndrome." This condition allows the translocation of harmful substances such as endotoxins into the bloodstream, contributing to systemic inflammation and exacerbating disease states [50].

Dietary interventions are pivotal in addressing microbiome dysbiosis. Recent findings suggest that an unbalanced diet, characterized by excessive intake of simple carbohydrates, saturated fats, and processed foods, is directly linked to dysbiosis. Conversely, diets rich in nuts, vegetables, fruits, fish, and poultry promote a diverse and beneficial gut microbiota. Incorporating prebiotics and probiotics into the diet can further enhance microbial diversity and functionality, improving gut barrier integrity and overall health [50].

Emerging therapeutic strategies aim to restore microbial balance through dietary modifications. These include the use of probiotics, prebiotics, and synbiotics, which have shown promise in clinical settings. For instance, probiotics can introduce beneficial bacteria to the gut, while prebiotics serve as food for these microbes, fostering their growth and activity. Additionally, dietary supplements containing omega-3 fatty acids and vitamins have been shown to positively influence gut microbiota composition [42][50].

Furthermore, plant-derived compounds have been explored for their potential to inhibit enzymes linked to dysbiosis. For example, studies on herbal interventions have indicated that certain phytochemicals can effectively target enzymes associated with dysbiosis-induced diseases, thereby offering a natural approach to correcting microbial imbalances [51].

In summary, microbiome dysbiosis significantly contributes to disease pathogenesis by disrupting the gut barrier and promoting inflammation. Dietary interventions play a crucial role in managing dysbiosis, offering personalized and effective strategies to restore microbial balance and improve health outcomes. Ongoing research into the interplay between diet, microbiota, and disease will likely lead to more refined therapeutic approaches tailored to individual microbiome profiles [42][50][51].

6 Future Directions and Research Gaps ​

6.1 Emerging Technologies in Microbiome Research ​

Microbiome dysbiosis, characterized by an imbalance in the composition and function of microbial communities, plays a significant role in the pathogenesis of various diseases. The relationship between dysbiosis and disease is multifaceted, involving alterations in microbial diversity, metabolic functions, and immune responses.

Dysbiosis can lead to the disruption of homeostasis in the host, contributing to a range of conditions including cardiovascular diseases, diabetes, inflammatory bowel disease, and autoimmune disorders. For instance, alterations in the gastrointestinal tract microbiome have been linked to the pathophysiology of diabetes mellitus, where microbial dysbiosis affects gut fermentation profiles and intestinal wall integrity, resulting in metabolic endotoxemia and low-grade inflammation (Sohail et al. 2017) [14]. Furthermore, dysbiosis has been implicated in periodontitis, where an imbalance in the oral microbiome can lead to systemic health issues, including diabetes and cardiovascular diseases (Yost et al. 2017) [13].

The mechanisms through which dysbiosis contributes to disease include the modulation of host immune responses and the induction of chronic inflammation. For example, dysbiosis has been shown to disrupt T-cell homeostasis, leading to an imbalance in T-cell subpopulations that are critical for maintaining immune function (Lee and Kim 2017) [16]. This dysregulation can promote the development of autoimmune and inflammatory diseases, as evidenced by its association with conditions such as rheumatoid arthritis and asthma.

Emerging research technologies, such as metatranscriptomic analysis, have enhanced our understanding of dysbiosis and its role in disease. These technologies allow for the identification of specific microbial signatures associated with diseases, thus providing insights into potential therapeutic targets. For example, the identification of potassium ion transport as a key element in the pathogenesis of periodontitis underscores the importance of environmental signals in modifying the behavior of the oral microbiome (Yost et al. 2017) [13].

Future research directions should focus on elucidating the causal relationships between dysbiosis and disease, as well as identifying the specific microbial taxa and functional pathways involved. Additionally, the exploration of therapeutic interventions aimed at restoring microbial balance, such as probiotics and fecal microbiota transplantation, holds promise for managing dysbiosis-related diseases (Kapoor et al. 2022) [52]. Overall, a comprehensive understanding of microbiome dysbiosis and its implications for health and disease will be essential for the development of innovative diagnostic and therapeutic strategies.

6.2 Need for Longitudinal Studies ​

Microbiome dysbiosis, defined as an imbalance in the microbial community structure, is increasingly recognized as a significant factor contributing to various diseases. The loss of microbial diversity and the alteration in the composition of gut microbiota can lead to inflammation and the onset of chronic diseases. This relationship has been substantiated by multiple studies, which highlight the role of dysbiosis in conditions such as obesity, diabetes, cardiovascular diseases, and even neurological disorders like Parkinson's disease and schizophrenia.

The research indicates that dysbiosis is often characterized by a reduction in beneficial bacteria and an increase in pathogenic microorganisms. For instance, in a study by Wilkins et al. (2019), it was found that individuals with chronic diseases exhibited a statistically significant association with recent antibiotic use, which was linked to alterations in gut microbiota composition and a loss of microbial diversity. Specifically, genera such as Bacteroides, Prevotella, and Ruminococcus were identified as common dysbiotic taxa in disease populations, suggesting that these alterations are not merely incidental but may actively contribute to disease pathology[6].

Moreover, dysbiosis has been implicated in critical illness, where it can exacerbate comorbidities and organ dysfunction. Jacobs et al. (2017) noted that critically ill patients often exhibit lower microbial diversity and overgrowth of certain bacterial genera, indicating that dysbiosis might play a more severe role in acute health crises than previously understood. The implications of dysbiosis extend beyond gastrointestinal disorders, affecting systemic health and immune responses, thus emphasizing the need for a comprehensive understanding of its mechanisms[24].

Despite the growing body of evidence linking dysbiosis to various diseases, significant research gaps remain, particularly concerning the causal relationships and the underlying mechanisms. While cross-sectional studies have established associations between dysbiosis and diseases, longitudinal studies are essential to confirm causative effects. For instance, the impact of early-life dysbiosis on long-term health outcomes is still not fully understood. Parkin et al. (2021) highlighted that the gut microbiome's development is highly plastic during infancy, and dysbiosis during this critical period can have lasting effects on the immune system and the risk of developing inflammatory diseases[23].

Furthermore, the need for longitudinal studies is underscored by the complex interplay between dysbiosis and various environmental factors, including diet, antibiotic use, and lifestyle. A systematic review by Van Zyl et al. (2022) emphasized that while short-term studies provide valuable insights into the immediate effects of antibiotics on microbiota diversity, understanding the long-term consequences of such interventions is crucial for developing effective treatment strategies[53].

In conclusion, while dysbiosis is clearly linked to the development and progression of numerous diseases, future research must focus on longitudinal studies to unravel the complexities of these relationships. Such studies should aim to establish causative links, explore the mechanisms of dysbiosis-induced pathology, and evaluate the efficacy of interventions aimed at restoring microbiome balance as potential therapeutic strategies. This approach will be vital in addressing the health implications of dysbiosis and developing targeted therapies to mitigate its adverse effects on human health.

7 Conclusion ​

This review highlights the intricate relationship between microbiome dysbiosis and disease pathogenesis, emphasizing the need for a comprehensive understanding of the mechanisms involved. Key findings indicate that dysbiosis disrupts immune homeostasis, contributes to chronic inflammation, and alters metabolic functions, leading to various health complications, including metabolic disorders, autoimmune diseases, and mental health conditions. Current research underscores the importance of restoring microbial balance through interventions such as probiotics, prebiotics, and fecal microbiota transplantation. However, significant research gaps remain, particularly regarding the causal relationships and long-term effects of dysbiosis. Future studies should prioritize longitudinal approaches to elucidate these connections and optimize therapeutic strategies aimed at managing dysbiosis-related diseases. Ultimately, advancing our understanding of microbiome dynamics will pave the way for innovative treatments that harness the microbiome to improve health outcomes.

References ​

  • [1] Kaijian Hou;Zhuo-Xun Wu;Xuan-Yu Chen;Jing-Quan Wang;Dongya Zhang;Chuanxing Xiao;Dan Zhu;Jagadish B Koya;Liuya Wei;Jilin Li;Zhe-Sheng Chen. Microbiota in health and diseases.. Signal transduction and targeted therapy(IF=52.7). 2022. PMID:35461318. DOI: 10.1038/s41392-022-00974-4.
  • [2] Chiara Pellicano;Giorgia Leodori;Giuseppe Pietro Innocenti;Antonietta Gigante;Edoardo Rosato. Microbiome, Autoimmune Diseases and HIV Infection: Friends or Foes?. Nutrients(IF=5.0). 2019. PMID:31684052. DOI: 10.3390/nu11112629.
  • [3] Noah Weinstein;Brandon Garten;Jonathan Vainer;Dulce Minaya;Krzysztof Czaja. Managing the Microbiome: How the Gut Influences Development and Disease.. Nutrients(IF=5.0). 2020. PMID:33383647. DOI: 10.3390/nu13010074.
  • [4] Nermin Kamal Saeed;Mohammed Al-Beltagi;Adel Salah Bediwy;Yasser El-Sawaf;Osama Toema. Gut microbiota in various childhood disorders: Implication and indications.. World journal of gastroenterology(IF=5.4). 2022. PMID:35664966. DOI: 10.3748/wjg.v28.i18.1875.
  • [5] Maayan Levy;Aleksandra A Kolodziejczyk;Christoph A Thaiss;Eran Elinav. Dysbiosis and the immune system.. Nature reviews. Immunology(IF=60.9). 2017. PMID:28260787. DOI: 10.1038/nri.2017.7.
  • [6] Lamont J Wilkins;Manoj Monga;Aaron W Miller. Defining Dysbiosis for a Cluster of Chronic Diseases.. Scientific reports(IF=3.9). 2019. PMID:31501492. DOI: 10.1038/s41598-019-49452-y.
  • [7] Ancuta Lupu;Elena Jechel;Cristina Maria Mihai;Elena Cristina Mitrofan;Silvia Fotea;Iuliana Magdalena Starcea;Ileana Ioniuc;Adriana Mocanu;Dragos Catalin Ghica;Alina Popp;Dragos Munteanu;Maria Oana Sasaran;Delia Lidia Salaru;Vasile Valeriu Lupu. The Footprint of Microbiome in Pediatric Asthma-A Complex Puzzle for a Balanced Development.. Nutrients(IF=5.0). 2023. PMID:37513696. DOI: 10.3390/nu15143278.
  • [8] Yong-Guo Zhang;Yinglin Xia;Jilei Zhang;Shreya Deb;Shari Garrett;Jun Sun. Intestinal vitamin D receptor protects against extraintestinal breast cancer tumorigenesis.. Gut microbes(IF=11.0). 2023. PMID:37074210. DOI: 10.1080/19490976.2023.2202593.
  • [9] Soumik Das;Ramanathan Gnanasambandan. Intestinal microbiome diversity of diabetic and non-diabetic kidney disease: Current status and future perspective.. Life sciences(IF=5.1). 2023. PMID:36682521. DOI: 10.1016/j.lfs.2023.121414.
  • [10] Agnieszka Zawada;Anna Maria Rychter;Alicja Ewa Ratajczak;Agata Lisiecka-Masian;Agnieszka Dobrowolska;Iwona Krela-Kaźmierczak. Does Gut-Microbiome Interaction Protect against Obesity and Obesity-Associated Metabolic Disorders?. Microorganisms(IF=4.2). 2020. PMID:33374597. DOI: 10.3390/microorganisms9010018.
  • [11] Siau Wui Chin;Zheng Yao Low;Wei Qi Tan;Adzzie Shazleen Azman. Microbiota-Host Interactions: Exploring Their Dynamics and Contributions to Human Diseases.. MicrobiologyOpen(IF=4.6). 2025. PMID:40770906. DOI: 10.1002/mbo3.70043.
  • [12] Georgina L Hold;Megan Smith;Charlie Grange;Euan Robert Watt;Emad M El-Omar;Indrani Mukhopadhya. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?. World journal of gastroenterology(IF=5.4). 2014. PMID:24574795. DOI: 10.3748/wjg.v20.i5.1192.
  • [13] Susan Yost;Ana E Duran-Pinedo;Keerthana Krishnan;Jorge Frias-Lopez. Potassium is a key signal in host-microbiome dysbiosis in periodontitis.. PLoS pathogens(IF=4.9). 2017. PMID:28632755. DOI: 10.1371/journal.ppat.1006457.
  • [14] Muhammad U Sohail;Asmaa Althani;Haseeb Anwar;Roberto Rizzi;Hany E Marei. Role of the Gastrointestinal Tract Microbiome in the Pathophysiology of Diabetes Mellitus.. Journal of diabetes research(IF=3.4). 2017. PMID:29082264. DOI: 10.1155/2017/9631435.
  • [15] Michael Kriss;Keith Z Hazleton;Nichole M Nusbacher;Casey G Martin;Catherine A Lozupone. Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery.. Current opinion in microbiology(IF=7.5). 2018. PMID:30036705. DOI: 10.1016/j.mib.2018.07.003.
  • [16] Naeun Lee;Wan-Uk Kim. Microbiota in T-cell homeostasis and inflammatory diseases.. Experimental & molecular medicine(IF=12.9). 2017. PMID:28546563. DOI: 10.1038/emm.2017.36.
  • [17] George Hajishengallis;Richard P Darveau;Michael A Curtis. The keystone-pathogen hypothesis.. Nature reviews. Microbiology(IF=103.3). 2012. PMID:22941505. DOI: 10.1038/nrmicro2873.
  • [18] Victoria Ronan;Rummanu Yeasin;Erika C Claud. Childhood Development and the Microbiome-The Intestinal Microbiota in Maintenance of Health and Development of Disease During Childhood Development.. Gastroenterology(IF=25.1). 2021. PMID:33307032. DOI: 10.1053/j.gastro.2020.08.065.
  • [19] Gobind Anand;Amir Zarrinpar;Rohit Loomba. Targeting Dysbiosis for the Treatment of Liver Disease.. Seminars in liver disease(IF=3.7). 2016. PMID:26870931. DOI: 10.1055/s-0035-1571276.
  • [20] Daniel H Leung;Dean Yimlamai. The intestinal microbiome and paediatric liver disease.. The lancet. Gastroenterology & hepatology(IF=38.6). 2017. PMID:28497760. DOI: 10.1016/S2468-1253(16)30241-2.
  • [21] Cristina Llorente;Bernd Schnabl. The gut microbiota and liver disease.. Cellular and molecular gastroenterology and hepatology(IF=7.4). 2015. PMID:26090511. DOI: 10.1016/j.jcmgh.2015.04.003.
  • [22] Hiroko Nagao-Kitamoto;Sho Kitamoto;Peter Kuffa;Nobuhiko Kamada. Pathogenic role of the gut microbiota in gastrointestinal diseases.. Intestinal research(IF=3.9). 2016. PMID:27175113. DOI: 10.5217/ir.2016.14.2.127.
  • [23] Kimberley Parkin;Claus T Christophersen;Valerie Verhasselt;Matthew N Cooper;David Martino. Risk Factors for Gut Dysbiosis in Early Life.. Microorganisms(IF=4.2). 2021. PMID:34683389. DOI: 10.3390/microorganisms9102066.
  • [24] Max C Jacobs;Bastiaan W Haak;Floor Hugenholtz;W Joost Wiersinga. Gut microbiota and host defense in critical illness.. Current opinion in critical care(IF=3.4). 2017. PMID:28548992. DOI: 10.1097/MCC.0000000000000424.
  • [25] Yao Shen;Nairui Fan;Shu-Xia Ma;Xin Cheng;Xuesong Yang;Guang Wang. Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy.. MedComm(IF=10.7). 2025. PMID:40255918. DOI: 10.1002/mco2.70168.
  • [26] Nathalie Coutry;Imène Gasmi;Fabien Herbert;Philippe Jay. Mechanisms of intestinal dysbiosis: new insights into tuft cell functions.. Gut microbes(IF=11.0). 2024. PMID:39042424. DOI: 10.1080/19490976.2024.2379624.
  • [27] Despoina Gyriki;Christos G Nikolaidis;Eugenia Bezirtzoglou;Chrysa Voidarou;Elisavet Stavropoulou;Christina Tsigalou. The gut microbiota and aging: interactions, implications, and interventions.. Frontiers in aging(IF=4.3). 2025. PMID:40438731. DOI: 10.3389/fragi.2025.1452917.
  • [28] Massimiliano Cazzaniga;Giordano Bruno Zonzini;Francesco Di Pierro;Sara Moricoli;Alexander Bertuccioli. Gut Microbiota, Metabolic Disorders and Breast Cancer: Could Berberine Turn Out to Be a Transversal Nutraceutical Tool? A Narrative Analysis.. International journal of molecular sciences(IF=4.9). 2022. PMID:36293390. DOI: 10.3390/ijms232012538.
  • [29] Natalia G Vallianou;Theodora Stratigou;Stylianos Tsagarakis. Microbiome and diabetes: Where are we now?. Diabetes research and clinical practice(IF=7.4). 2018. PMID:30342053. DOI: 10.1016/j.diabres.2018.10.008.
  • [30] Hamid Mostafavi Abdolmaleky;Jin-Rong Zhou. Gut Microbiota Dysbiosis, Oxidative Stress, Inflammation, and Epigenetic Alterations in Metabolic Diseases.. Antioxidants (Basel, Switzerland)(IF=6.6). 2024. PMID:39199231. DOI: 10.3390/antiox13080985.
  • [31] Mariangela Rondanelli;Sara Borromeo;Alessandro Cavioni;Clara Gasparri;Ilaria Gattone;Elisa Genovese;Alessandro Lazzarotti;Leonardo Minonne;Alessia Moroni;Zaira Patelli;Claudia Razza;Claudia Sivieri;Eugenio Marzio Valentini;Gaetan Claude Barrile. Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management.. Metabolites(IF=3.7). 2025. PMID:39997751. DOI: 10.3390/metabo15020127.
  • [32] Sorina Ispas;Liliana Ana Tuta;Mihaela Botnarciuc;Viorel Ispas;Sorana Staicovici;Sevigean Ali;Andreea Nelson-Twakor;Cristina Cojocaru;Alexandra Herlo;Adina Petcu. Metabolic Disorders, the Microbiome as an Endocrine Organ, and Their Relations with Obesity: A Literature Review.. Journal of personalized medicine(IF=3.0). 2023. PMID:38003917. DOI: 10.3390/jpm13111602.
  • [33] Mc Anto Antony;Aniqa Chowdhury;Dinesh Edem;Rishi Raj;Priyanshu Nain;Mansi Joglekar;Vipin Verma;Ravi Kant. Gut microbiome supplementation as therapy for metabolic syndrome.. World journal of diabetes(IF=4.6). 2023. PMID:37970133. DOI: 10.4239/wjd.v14.i10.1502.
  • [34] Aneta Sokal-Dembowska;Ewelina Polak-Szczybyło;Kacper Helma;Patrycja Musz;Maciej Setlik;Weronika Fic;Dawid Wachowiak;Sara Jarmakiewicz-Czaja. Physical Activity and Metabolic Disorders-What Does Gut Microbiota Have to Do with It?. Current issues in molecular biology(IF=3.0). 2025. PMID:40864784. DOI: 10.3390/cimb47080630.
  • [35] Zhuo Huang;Qinyan Yao;Shuang Ma;Jinjie Zhou;Xiaoxuan Wang;Qingguo Meng;Yaxin Liu;Zihan Yu;Xin Chen. The synergistic role of gut microbiota and RNA in metabolic diseases: mechanisms and therapeutic insights.. Frontiers in microbiology(IF=4.5). 2025. PMID:39944642. DOI: 10.3389/fmicb.2025.1504395.
  • [36] Nafees Ahmed;Vishwas Gaur;Madhu Kamle;Abhishek Chauhan;Ritu Chauhan;Pradeep Kumar;Namita Ashish Singh. Microbiome-based therapeutics for metabolic disorders: harnessing microbial intrusions for treatment.. Frontiers in medical technology(IF=3.8). 2025. PMID:41246285. DOI: 10.3389/fmedt.2025.1695329.
  • [37] Syeda Noor Fatima;Fariha Arif;Rahuf Khalid;Madiha Khan;Khalida Naseem. Immunomodulatory role of gut microbiota in autoimmune disorders and the advancement of gut microbiota based therapeutic strategies.. Microbial pathogenesis(IF=3.5). 2025. PMID:40645350. DOI: 10.1016/j.micpath.2025.107882.
  • [38] Serena Martinelli;Giulia Nannini;Fabio Cianchi;Francesco Coratti;Amedeo Amedei. The Impact of Microbiota-Immunity-Hormone Interactions on Autoimmune Diseases and Infection.. Biomedicines(IF=3.9). 2024. PMID:38540229. DOI: 10.3390/biomedicines12030616.
  • [39] Alexis Vogelzang;Matteo M Guerrini;Nagahiro Minato;Sidonia Fagarasan. Microbiota - an amplifier of autoimmunity.. Current opinion in immunology(IF=5.8). 2018. PMID:30248521. DOI: 10.1016/j.coi.2018.09.003.
  • [40] Jian Tan;Jemma Taitz;Ralph Nanan;Georges Grau;Laurence Macia. Dysbiotic Gut Microbiota-Derived Metabolites and Their Role in Non-Communicable Diseases.. International journal of molecular sciences(IF=4.9). 2023. PMID:37894934. DOI: 10.3390/ijms242015256.
  • [41] Yu-Ling Tsai;Tzu-Lung Lin;Chih-Jung Chang;Tsung-Ru Wu;Wei-Fan Lai;Chia-Chen Lu;Hsin-Chih Lai. Probiotics, prebiotics and amelioration of diseases.. Journal of biomedical science(IF=12.1). 2019. PMID:30609922. DOI: 10.1186/s12929-018-0493-6.
  • [42] Hanif Ullah;Safia Arbab;Chengting Chang;Saira Bibi;Nehaz Muhammad;Sajid Ur Rehman; Suleman;Irfan Ullah;Inam Ul Hassan;Yali Tian;Ka Li. Gut microbiota therapy in gastrointestinal diseases.. Frontiers in cell and developmental biology(IF=4.3). 2025. PMID:40078367. DOI: 10.3389/fcell.2025.1514636.
  • [43] Gabriel Florin Răzvan Mogoş;Monica Manciulea Profir;Robert-Mihai Enache;Luciana Alexandra Pavelescu;Oana Alexandra Popescu Roşu;Sanda Maria Cretoiu;Ileana Marinescu. Intestinal Microbiota in Early Life: Latest Findings Regarding the Role of Probiotics as a Treatment Approach for Dysbiosis.. Nutrients(IF=5.0). 2025. PMID:40647176. DOI: 10.3390/nu17132071.
  • [44] Lucas de Freitas Pedrosa;Paul de Vos;João Paulo Fabi. From Structure to Function: How Prebiotic Diversity Shapes Gut Integrity and Immune Balance.. Nutrients(IF=5.0). 2024. PMID:39770907. DOI: 10.3390/nu16244286.
  • [45] Fabrizio Fanizzi;Ferdinando D'Amico;Isadora Zanotelli Bombassaro;Alessandra Zilli;Federica Furfaro;Tommaso Lorenzo Parigi;Clelia Cicerone;Gionata Fiorino;Laurent Peyrin-Biroulet;Silvio Danese;Mariangela Allocca. The Role of Fecal Microbiota Transplantation in IBD.. Microorganisms(IF=4.2). 2024. PMID:39338430. DOI: 10.3390/microorganisms12091755.
  • [46] Henry Sutanto;Elisa Elisa;Betty Rachma;Deasy Fetarayani. Gut Microbiome Modulation in Allergy Treatment: The Role of Fecal Microbiota Transplantation.. The American journal of medicine(IF=5.3). 2025. PMID:39855612. DOI: 10.1016/j.amjmed.2025.01.005.
  • [47] Byron P Vaughn;Kevin M Rank;Alexander Khoruts. Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease.. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association(IF=12.0). 2019. PMID:30055267. DOI: 10.1016/j.cgh.2018.07.026.
  • [48] Mehdi Karimi;Niyousha Shirsalimi;Zahra Hashempour;Hossein Salehi Omran;Eshagh Sedighi;Farzan Beigi;Masoud Mortezazadeh. Safety and efficacy of fecal microbiota transplantation (FMT) as a modern adjuvant therapy in various diseases and disorders: a comprehensive literature review.. Frontiers in immunology(IF=5.9). 2024. PMID:39391303. DOI: 10.3389/fimmu.2024.1439176.
  • [49] Meng-Que Xu;Hai-Long Cao;Wei-Qiang Wang;Shan Wang;Xiao-Cang Cao;Fang Yan;Bang-Mao Wang. Fecal microbiota transplantation broadening its application beyond intestinal disorders.. World journal of gastroenterology(IF=5.4). 2015. PMID:25574083. DOI: 10.3748/wjg.v21.i1.102.
  • [50] Ana Beatriz Marcari;Aline Dias Paiva;Claudio Roberto Simon;Maria Emilia Soares Martins Dos Santos. Leaky Gut Syndrome: An Interplay Between Nutrients and Dysbiosis.. Current nutrition reports(IF=5.5). 2025. PMID:39890659. DOI: 10.1007/s13668-025-00614-7.
  • [51] Shivani Singhal;Vibha Rani. Study to Explore Plant-Derived Trimethylamine Lyase Enzyme Inhibitors to Address Gut Dysbiosis.. Applied biochemistry and biotechnology(IF=3.3). 2022. PMID:34822060. DOI: 10.1007/s12010-021-03747-x.
  • [52] Bhupinder Kapoor;Monica Gulati;Pooja Rani;Reena Gupta. Psoriasis: Interplay between dysbiosis and host immune system.. Autoimmunity reviews(IF=8.3). 2022. PMID:35964945. DOI: 10.1016/j.autrev.2022.103169.
  • [53] Kristien Nel Van Zyl;Siphiwe R Matukane;Bianca L Hamman;Andrew C Whitelaw;Mae Newton-Foot. Effect of antibiotics on the human microbiome: a systematic review.. International journal of antimicrobial agents(IF=4.6). 2022. PMID:34929293. DOI: 10.1016/j.ijantimicag.2021.106502.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

microbiome dysbiosis · disease · immune dysregulation · inflammation · metabolic processes

© 2025 MaltSci